The delays could have implications for some countries still facing low vaccination rates and those in desperate need of vaccine supply.
The company finalized a deal last week to supply 1.1 billion doses of its shot to low- and middle-income countries participating in the COVAX Facility, a global initiative aimed at equitable access to the vaccines.Novavax previously said it expected to complete requests for regulatory authorizations of its vaccine in the U.S., the U.K.
and other European countries by the end of June, according to the Wall Street Journal. But the company said in an earnings call Monday that it now expects to complete the regulatory filings during the third quarter of 2021. "We know that we’re delayed from where we thought.